Jutta K. Preiksaitis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jutta K. Preiksaitis has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
X.L. Pang
2 shared publicationsB. LeBlanc
1 shared publicationB. Leblanc
1 shared publicationJ. Fenton
Virology, Provincial Public Health Laboratory, Edmonton/CANADA
1 shared publicationJayne M. Fenton
1 shared publicationK. Doucette
1 shared publication
Latest Publications
- 27 July 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90, 668
OPTIMIZING LABORATORY SCREENING FOR EPSTEIN BARR VIRUS SEROSTATUS IN SOLID ORGAN TRANSPLANT RECIPIENTS
- 27 July 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90, 668
OPTIMIZING LABORATORY SCREENING FOR EPSTEIN BARR VIRUS SEROSTATUS IN SOLID ORGAN TRANSPLANT RECIPIENTS
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S44
Monitoring BK virus in renal allograft recipients using quantitative PCR
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S44
Monitoring BK virus in renal allograft recipients using quantitative PCR
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S42
Detecting BK viruria with four assays in renal transplant recipients
- 31 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 36, S42
Detecting BK viruria with four assays in renal transplant recipients
- Open Access
- 1 July 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (s1) , S38-S46
Diagnosis and Management of Posttransplant Lymphoproliferative Disorder in Solid‐Organ Transplant Recipients
The Epstein-Barr virus (EBV) has a pivotal pathophysiologic role in the development of most lymphoproliferative disorders that occur after solid-orga
- 1 July 2001
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (s1) , S38-S46
Open AccessDiagnosis and Management of Posttransplant Lymphoproliferative Disorder in Solid‐Organ Transplant Recipients
The Epstein-Barr virus (EBV) has a pivotal pathophysiologic role in the development of most lymphoproliferative disorders that occur after solid-orga
- 1 June 2001
- Published by Wiley in Transplant Infectious Disease
- Vol. 3 (2) , 56-59
Epstein–Barr virus infection and malignancy in solid organ transplant recipients: strategies for prevention and treatment
- 1 June 2001
- Published by Wiley in Transplant Infectious Disease
- Vol. 3 (2) , 56-59
Epstein–Barr virus infection and malignancy in solid organ transplant recipients: strategies for prevention and treatment
- 1 December 1997
- Published by Wolters Kluwer Health in Transplantation
- Vol. 64 (12) , 1775-1780
SEROLOGIC RESPONSES TO HEPATITIS C VIRUS IN SOLID ORGAN TRANSPLANT RECIPIENTS1
Hepatitis C (HCV) infection is known to have been transmitted by both blood transfusion and donor organs. We sought to determine the historical incidence of donor- and transfusion-acquired HCV infection in kidney transplant (RTx) and heart transplant (HTx) recipients at our center and to study the kinetics of seroconversion to HCV. A bank of sera collected from organ donors (388 RTx and 88 HTx) who received allografts between January 1984 and April 1992 was screened for anti-HCV using a third generation enzyme immunoassay. Recipient sera collected before transplant (preTx), at 1 year after transplant, and at last follow-up were tested. Fresh follow-up sera on all surviving anti-HCV-positive (+) RTx and HTx, all anti-HCV-negative (-) HTx, and a subset of 85 anti-HCV- RTx were assayed for HCV RNA using an reverse transcriptase-polymerase chain reaction assay. Twenty-four of 388 RTx (6.2%) and 2 of 88 HTx (2.3%) were anti-HCV+ preTx. Eight of 218 (3.7%) organ donors were anti-HCV+. Six of the seven (85.7%) anti-HCV+ donors with adequate recipient follow-up transmitted HCV infection to one or more recipients. Nineteen of 313 RTx (6.1%) and 8 of 72 HTx (11.1%) with follow-up≥1 year seroconverted to anti-HCV. One of 85 (1.2%) anti-HCV- RTx and 3 of 44 (6.8%) anti-HCV- HTx were HCV RNA+ when tested at last follow-up. Five cases of de novo HCV infection occurred after the introduction of first generation anti-HCV screening of donors. Persistent viremia (HCV RNA+) at last follow-up was observed in 70.6% (12/17) RTx anti-HCV+ preTx. Fourteen of 15 (93.3%) RTx and 9 of 9 (100%) HTx with de novo HCV infection had persistent viremia. Seroconversion was more delayed in HTx than RTx ( P =0.0572, log-rank Mantel-Cox statistic) although both groups demonstrated an impaired humoral response to HCV when compared with the immunocompetent host. Organ donor- and transfusion-acquired HCV infection was common in RTx and HTx transplanted before the introduction of second generation anti-HCV screening in 1992. Serologic responses to HCV are often delayed and sometimes absent in these patients. Assays for HCV RNA should be considered as a screening test for the detection of HCV infection in this population. Serologic responses to HCV were more impaired in HTx compared with RTx, which may reflect the more intensive immunosuppressive regimens given to HTx at our center.
- 1 December 1997
- Published by Wolters Kluwer Health in Transplantation
- Vol. 64 (12) , 1775-1780
SEROLOGIC RESPONSES TO HEPATITIS C VIRUS IN SOLID ORGAN TRANSPLANT RECIPIENTS1
Hepatitis C (HCV) infection is known to have been transmitted by both blood transfusion and donor organs. We sought to determine the historical incidence of donor- and transfusion-acquired HCV infection in kidney transplant (RTx) and heart transplant (HTx) recipients at our center and to study the kinetics of seroconversion to HCV. A bank of sera collected from organ donors (388 RTx and 88 HTx) who received allografts between January 1984 and April 1992 was screened for anti-HCV using a third generation enzyme immunoassay. Recipient sera collected before transplant (preTx), at 1 year after transplant, and at last follow-up were tested. Fresh follow-up sera on all surviving anti-HCV-positive (+) RTx and HTx, all anti-HCV-negative (-) HTx, and a subset of 85 anti-HCV- RTx were assayed for HCV RNA using an reverse transcriptase-polymerase chain reaction assay. Twenty-four of 388 RTx (6.2%) and 2 of 88 HTx (2.3%) were anti-HCV+ preTx. Eight of 218 (3.7%) organ donors were anti-HCV+. Six of the seven (85.7%) anti-HCV+ donors with adequate recipient follow-up transmitted HCV infection to one or more recipients. Nineteen of 313 RTx (6.1%) and 8 of 72 HTx (11.1%) with follow-up≥1 year seroconverted to anti-HCV. One of 85 (1.2%) anti-HCV- RTx and 3 of 44 (6.8%) anti-HCV- HTx were HCV RNA+ when tested at last follow-up. Five cases of de novo HCV infection occurred after the introduction of first generation anti-HCV screening of donors. Persistent viremia (HCV RNA+) at last follow-up was observed in 70.6% (12/17) RTx anti-HCV+ preTx. Fourteen of 15 (93.3%) RTx and 9 of 9 (100%) HTx with de novo HCV infection had persistent viremia. Seroconversion was more delayed in HTx than RTx ( P =0.0572, log-rank Mantel-Cox statistic) although both groups demonstrated an impaired humoral response to HCV when compared with the immunocompetent host. Organ donor- and transfusion-acquired HCV infection was common in RTx and HTx transplanted before the introduction of second generation anti-HCV screening in 1992. Serologic responses to HCV are often delayed and sometimes absent in these patients. Assays for HCV RNA should be considered as a screening test for the detection of HCV infection in this population. Serologic responses to HCV were more impaired in HTx compared with RTx, which may reflect the more intensive immunosuppressive regimens given to HTx at our center.